SCHY - ETF AI Analysis

Top Page

Schwab International Dividend Equity ETF (SCHY)

Rating:61Neutral

Price Target:―

The Schwab International Dividend Equity ETF (SCHY) demonstrates a balanced performance, supported by strong contributions from holdings like TotalEnergies SE and GlaxoSmithKline. TotalEnergies benefits from solid financial performance, attractive valuation, and positive technical indicators, while GlaxoSmithKline's growth outlook is bolstered by strategic initiatives and favorable valuation metrics. However, weaker momentum in holdings such as Wesfarmers Limited and BHP Group, both showing bearish technical trends and potential overvaluation, slightly dampens the overall rating. Investors should also note the ETF's exposure to multiple sectors, which helps diversify risk but requires monitoring for sector-specific challenges.

Positive Factors

Strong Year-to-Date Performance

The ETF has delivered solid gains so far this year, reflecting strong overall momentum.

Low Expense Ratio

With a very low expense ratio, this ETF allows investors to keep more of their returns compared to higher-cost funds.

Global Diversification

The fund’s exposure to multiple countries, including the UK, Australia, and Switzerland, reduces reliance on any single market.

Negative Factors

Underperforming Holdings

Some top holdings, like TotalEnergies SE, have shown weak performance, which could drag on overall returns.

Limited Technology Exposure

The ETF has minimal exposure to the technology sector, potentially missing out on growth opportunities in this area.

High Concentration in Consumer Defensive

The fund’s largest sector allocation is Consumer Defensive, which may limit upside potential during economic growth periods.

SCHY vs. SPDR S&P 500 ETF (SPY)

AUM1.78B

RegionGlobal Ex-U.S.

Expense Ratio0.08%

Beta0.36

IssuerSchwab

Inception DateApr 29, 2021

Dividend Yield3.5%

Asset ClassEquity

Index TrackedDow Jones International Dividend 100 Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume629,542

30 Day Avg. Volume470,281

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

31.10

Price Target Upside― Downside

Rating ConsensusHold

Number of Analyst Covering68

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

SCHY Summary

The Schwab International Dividend Equity ETF (SCHY) is an investment fund that focuses on high-dividend-paying companies from developed countries outside the U.S. It tracks the Dow Jones International Dividend 100 Index and includes well-known companies like GlaxoSmithKline and Roche Holding AG. SCHY is ideal for investors seeking steady income and global diversification, as it invests in industries like healthcare, consumer goods, and financials across regions like the UK, Australia, and Japan. However, new investors should be aware that the ETF’s performance depends on international markets, which can be affected by currency fluctuations and global economic conditions.

How much will it cost me?The Schwab International Dividend Equity ETF (SCHY) has an expense ratio of 0.08%, which means you’ll pay $0.80 per year for every $1,000 invested. This is lower than average because SCHY is passively managed, tracking an index rather than relying on active stock picking.

What would affect this ETF?SCHY's focus on high dividend yields from international markets could benefit from stable economic growth in developed countries outside the U.S., as well as increased demand for defensive sectors like Consumer Defensive and Health Care during uncertain times. However, the ETF may face challenges from rising interest rates, which can make dividend-paying stocks less attractive, and potential regulatory changes or economic slowdowns in key regions where its top holdings operate. Geographic diversification helps mitigate some risks, but currency fluctuations and geopolitical tensions could also impact performance.

SCHY Top 10 Holdings

SCHY is leaning heavily on health care giants like Roche Holding AG and GlaxoSmithKline, which have been steady performers thanks to strong pipelines and cash flow management. Consumer defensive names like British American Tobacco are also contributing positively, buoyed by robust dividends and strategic initiatives. However, Wesfarmers Limited is lagging, with bearish technical trends holding back its potential. The fund’s focus on high-yielding international equities creates a diverse mix, but its tilt toward health care and consumer defensive sectors suggests a cautious approach to global market volatility.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
BHP	BHP Group Ltd	4.51%	$79.43M	AU$250.68B	31.56%	68 Neutral
ROG	Roche Holding AG	4.24%	$74.71M	CHF276.02B	52.12%	73 Outperform
ENEL	Enel S.p.A.	4.04%	$71.18M	€94.41B	31.34%	67 Neutral
4528	ONO Pharmaceutical Co	4.04%	$71.18M	¥1.07T	20.78%	75 Outperform
WES	Wesfarmers Limited	3.99%	$70.20M	AU$94.22B	25.50%	68 Neutral
GSK	GlaxoSmithKline	3.91%	$68.89M	£74.55B	33.66%	77 Outperform
DHL	DHL Group	3.90%	$68.69M	€53.14B	36.02%	76 Outperform
BATS	British American Tobacco	3.88%	$68.29M	£94.21B	46.05%	71 Outperform
TTE	TotalEnergies SE	3.83%	$67.37M	€122.39B	-1.39%	78 Outperform
0NQM	Vinci SA	3.75%	$65.92M	€64.83B	16.20%	76 Outperform

SCHY Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

29.33

Positive

100DMA

28.54

Positive

200DMA

27.35

Positive

Market Momentum

MACD

0.26

Positive

RSI

63.16

Neutral

STOCH

84.29

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SCHY, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 29.97, equal to the 50-day MA of 29.33, and equal to the 200-day MA of 27.35, indicating a bullish trend. The MACD of 0.26 indicates Positive momentum. The RSI at 63.16 is Neutral, neither overbought nor oversold. The STOCH value of 84.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SCHY.

SCHY Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
SCHY	―	―	$1.78B	0.08%	―
FVD	―	―	$8.48B	0.61%	―
FDVV	―	―	$8.29B	0.15%	―
DWX	―	―	$485.22M	0.45%	―
IDVZ	―	―	$130.85M	0.75%	―
VDI	―	―	$19.52M	0.39%	―

Performance Comparison

SCHY

Schwab International Dividend Equity ETF

30.22

7.36

32.20%

FVD

First Trust Value Line Dividend Index Fund

―

FDVV

Fidelity High Dividend ETF

―

DWX

SPDR S&P International Dividend ETF

―

IDVZ

Opal International Dividend Income ETF

―

VDI

Virtus International Dividend ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents